Table 4. H19 expression associated with clinical pathological characteristics (logistic regression).
| Clinical characteristics | Total (N) | Odds ratio in H19 expression | p-Value |
| Primary_disease (LGG vs.GBM) | 677 | 12.20 (7.50-20.92) | <0.001 |
| Age (<55 vs.≥55) | 677 | 4.55 (3.20-6.54) | <0.001 |
| Sample_type (primary tumor vs.recurrent tumor) | 677 | 2.06 (0.94-4.88) | 0.082 |
| Gender (female vs.male) | 675 | 1.07 (0.79-1.45) | 0.664 |
| Cancer_status (tumor free vs. with tumor) | 630 | 2.20 (1.58-3.08) | <0.001 |
| Radiation_therapy (NO vs.YES) | 615 | 2.47 (1.75-3.52) | <0.001 |
| Grade (G2 vs.G3) | 514 | 2.24 (1.57-3.19) | <0.001 |
| Laterality (left vs.right) | 503 | 1.02(0.72-1.45) | 0.893 |
| Seizure_history (NO vs.YES) | 480 | 0.82 (0.57-1.19) | 0.298 |
| Headache_history (NO vs.YES) | 465 | 1.21 (0.83-1.77) | 0.318 |
| Targeted_molecular_therapy (NO vs.YES) | 460 | 1.84 (1.27-2.68) | 0.001 |
| Mental_status_changes (NO vs.YES) | 459 | 1.40 (0.91-2.14) | 0.125 |
| Motor_movement_changes (NO vs.YES) | 457 | 1.27 (0.83-1.97) | 0.263 |
| Sensory_changes (NO vs.YES) | 454 | 1.39 (0.84-2.33) | 0.200 |
| New_tumor_event (NO vs.YES) | 446 | 1.93 (1.30-2.90) | 0.001 |
| Histological_type (Oligodendroglioma vs. Astrocytoma) | 385 | 1.75(1.15-2.70) | 0.009 |
| Family_history_of_cancer (NO vs.YES) | 342 | 0.95 (0.62-1.47) | 0.824 |
| Primary_therapy (complete remission vs.progressive disease) | 240 | 1.81 (1.09-3.05) | 0.024 |
a Categorical dependent variable, greater or less than the median expression level.